جست‌وجوی استاد و پژوهشگر

John Pandolfinoمشاهده پروفایل

استاد

• Esophageal Disorders
• Swallowing Disorders
• Gastroesophageal Reflux Disease (GERD)
• +۴ مورد دیگر

John Pandolfino serves as Chief of Gastroenterology and Hepatology and Hans Popper Professor of Medicine at Northwestern University's Feinberg School of Medicine, where he leads esophageal research and clinical programs. His expertise spans esophageal motor disorders, achalasia, GERD, and eosinophilic esophagitis with significant contributions to diagnostic standardization. His educational credentials include: MD from Loyola University/Stritch School of Medicine (1993) Internal Medicine Internship/Residency at Northwestern University McGaw Medical Center (1994-1996) Gastroenterology Fellowship at Northwestern University McGaw Medical Center (2001) Dr. Pandolfino's research integrates physiology and pathophysiology to address complex esophageal conditions. His work pioneers standardized esophageal function measurements, explores anxiety's role in swallowing disorders, and develops wireless monitoring for acid reflux therapy. Current investigations focus on predicting treatment responses in eosinophilic esophagitis and cognitive interventions for esophageal disease management. His 2025 publications reveal three key trends: (1) Advancement of cognitive/online interventions for symptom management, (2) Refinement of diagnostic protocols for achalasia using imaging, and (3) Critical evaluation of AI applications in motility interpretation. These works collectively enhance diagnostic precision while emphasizing human expertise in complex cases. Notable honors include: Election to American Society of Clinical Investigation (2018) AGA Research Mentor of the Year (2016) Raymond Clouse Award for Clinical Research (2009) Multiple mentorship awards from Feinberg School of Medicine As a dedicated mentor, Dr. Pandolfino has guided numerous trainees evidenced by his Research Mentor of the Year award and Outstanding Mentor recognition. His leadership extends to editorial roles at Gastroenterology and Clinical Gastroenterology and Hepatology , plus advisory positions for NIH and industry partners including Medtronic and Phathom Pharmaceuticals. Current grants support his work on cognitive interventions (ACCORD study) and physiological predictors of treatment response. He directs Northwestern's esophageal research program within the Division of Gastroenterology and Hepatology, collaborating with the Northwestern Scleroderma program and NUCATS. His team develops translational approaches for motility disorders while maintaining strong hospital affiliations with Northwestern Memorial Hospital.

Alexander V Misharinمشاهده پروفایل

دانشیار

• Pulmonary Immunology
• Interstitial Lung Disease
• Scleroderma-Associated Lung Fibrosis
• +۳ مورد دیگر

Alexander V Misharin serves as Associate Professor in the Department of Medicine (Pulmonary and Critical Care) at Northwestern University's Feinberg School of Medicine. He directs research at the Center for Human Immunobiology and Institute for Augmented Intelligence in Medicine, with affiliations spanning the Simpson Querrey Institute for Epigenetics, Northwestern Scleroderma Program, and Robert H. Lurie Comprehensive Cancer Center. His educational background includes: MD from Russian State Medical University (2002) PhD from Russian Academy of Medical Sciences (2004) Pediatrics Residency at Russian State Medical University (2004) Postdoctoral Fellowship in Endocrinology at Cedars-Sinai Medical Center (2008) Dr. Misharin's research focuses on pulmonary immunology and interstitial lung disease pathogenesis , particularly in scleroderma and post-COVID conditions. His lab investigates macrophage biology in fibrotic lung diseases using single-cell technologies and develops machine learning models for critical care applications. Current work integrates immunobiology with AI to predict disease progression in systemic sclerosis-associated ILD. His recent publications demonstrate a strong trend toward translational computational medicine , combining immunological profiling with predictive analytics. Key themes include machine learning applications in extubation prediction, pharmacokinetic modeling for ICU antibiotics, and biomarker discovery for scleroderma lung disease. Dr. Misharin leads the active clinical trial Molecular Biomarkers to Guide Therapy in Systemic Sclerosis-Associated Interstitial Lung Disease (IRB STU00218939), investigating blood, lung fluid, and skin biomarkers to personalize SSc-ILD treatment. He participates in Northwestern's $12 million NIH-funded lung neutrophil research initiative and contributes to the Simpson Querrey Lung Institute for Translational Science.

Isabel Mogollon Figueroaمشاهده پروفایل

پژوهشگر

• Genetics
• Developmental Biology
• Physiology
• +۳ مورد دیگر

Isabel Mogollon Figueroa is a Postdoctoral Researcher at the Finnish Institute of Molecular Medicine (FIMM), University of Helsinki, specializing in bioimage profiling. Her work integrates advanced imaging techniques with computational analysis to address questions in developmental biology, cancer research, and dermatology. Her research spans Genetics, Developmental Biology, and Physiology , with a focus on cellular mechanisms in development and disease. Key areas include: Bioimage Analysis and High-content Screening Cancer Tumor Microenvironment Profiling Oral Ectodermal Development and Disease Modeling Application of Deep Learning in Microscopy Her recent publications (2022-2025) demonstrate a strong trend in leveraging self-supervised learning and vision transformers for multiplexed microscopy images, particularly in cancer and developmental contexts. She contributes to pan-cancer studies and rare disease drug testing, highlighting interdisciplinary innovation at the intersection of molecular biology and artificial intelligence. Dr. Mogollon Figueroa actively participates in multiple research projects funded by the Academy of Finland and Cancer Foundation. She is involved in projects such as "Uncovering patterns in cancer cells with visual representation learning" (2021-2026) and "Syöpäsäätiö 24-26/HORVATH PETER" (2024-2026), focusing on computational oncology and image-based drug discovery. She collaborates within the Bioimage Profiling group at FIMM and is a member of the Euro Bioimaging ERIC board. Her work involves close collaboration with the iCAN community and participation in events like the Cytodata Hackathon, fostering interdisciplinary teamwork in bioimage informatics.

Molly J. Youssefمشاهده پروفایل

استادیار بالینی

• Pediatric Dermatology
• Contact Dermatitis
• Patch Testing
• +۳ مورد دیگر

Molly J. Youssef, M.D. is a Pediatric Dermatologist in the Department of Dermatology at Mayo Clinic Rochester. She holds dual board certification in Dermatology and Pediatrics with subspecialty certification in Pediatric Dermatology. Her clinical practice focuses on complex pediatric skin conditions including vascular anomalies, contact dermatitis, and dermatologic manifestations of systemic diseases. Her research centers on pediatric contact dermatitis with emphasis on: Computational analysis of patch testing copositivity patterns Trends in allergen reactivity across diverse populations Cost-effectiveness of diagnostic approaches Health disparities in dermatologic care Dr. Youssef's publication analysis reveals consistent output in high-impact dermatology journals, with 15 major publications between 2022-2025. Her work demonstrates methodological evolution from traditional retrospective reviews toward computational approaches and health equity research. Professional honors include: Arnold P Gold Humanism in Medicine Honor Society (2009) Summa Cum Laude, Luther College (2005) 2nd Year Honors, University of Minnesota Medical School (2007) She maintains active leadership in national dermatology organizations while directing key institutional committees at Mayo Clinic. Her clinical work directly informs her research through the Mayo Clinic's extensive patch testing program serving pediatric patients with complex dermatitis cases.

Andrew Leaskمشاهده پروفایل

استاد

• fibrosis
• tumor microenvironment
• matricellular proteins
• +۴ مورد دیگر

Dr. Andrew Leask is a Professor at the University of Saskatchewan, based at the Health Sciences Building in Saskatoon. He holds a BSc in Cell Biology from the University of British Columbia and a PhD in Molecular Genetics and Cell Biology from the University of Chicago. As a leading researcher in matrix biology, he investigates fibrosis, tumor microenvironments, and matricellular protein dynamics, with implications for scleroderma, melanoma, and connective tissue disorders. His research integrates molecular genetics, cell biology, and murine disease models to explore: Fibroblast plasticity in fibrotic and cancerous tissues CCN protein functions in cellular communication Therapeutic targeting of persistent fibrotic phenotypes Tumor neovascularization mechanisms Analysis of his recent publications (2018-2021) reveals consistent focus on: CCN1/CCN2 roles in skin fibrosis and cancer-associated fibroblast activation Verteporfin as a potential antifibrotic agent Murine models of melanoma and scleroderma Dr. Leask holds key editorial positions: Managing Editor, Journal of Cell Communication (instrumental in securing its first impact factor) Editorial Board, American Journal of Pathology He also serves on scientific boards for the American Society of Matrix Biology and International CCN Society. His laboratory has trained researchers now positioned at institutions including University of Toronto, Queen's University, and Genentech. While no lab name or website is specified, his group actively investigates fibroblast pathophysiology.

• Pulmonary Hypertension
• Molecular Mechanisms of Cardiovascular Disease
• Translational Medicine
• +۴ مورد دیگر

Professor Allan Lawrie is Chair of Pulmonary Vascular Diseases at the National Heart & Lung Institute, Faculty of Medicine, Imperial College London. He previously served as Professor of Translational Cardiopulmonary Science at the University of Sheffield (2018–2022), where he established a translational research program in Pulmonary Hypertension and co-founded the Donald Heath Centre for Pulmonary Hypertension Research. His academic journey includes a BSc (Hons) from Edinburgh Napier University and a PhD from the University of Sheffield. Research Focus Lawrie's research deciphers molecular mechanisms in pulmonary hypertension, emphasizing translational outcomes like novel therapies (e.g., an OPG-targeting antibody) and biomarkers. His work spans: Osteoprotegerin (OPG)/TRAIL axis pathology Cardiopulmonary disease mechanisms Therapeutic antibody development Clinical biomarker innovation Awards & Leadership Senior Fellowships: British Heart Foundation, Medical Research Council Prestigious Society Fellowships: American Heart Association, Pulmonary Vascular Research Institute Key Roles: Co-Director of BHF Doctoral Training Programme; Chair of NHLI Research Committee; Trustee of Scleroderma & Raynaud's UK Grant Leadership: Secured MRC DPFS award for antibody therapeutics Academic Contributions Lawrie co-founded PH Therapeutics Ltd to advance pulmonary hypertension treatments and mentors through Imperial's BHF training initiative. He champions open research as NHLI's Open Research Lead.

• Rheumatology
• Autoimmune Diseases
• Connective Tissue Disorders
• +۴ مورد دیگر

Louise C P Raun Diederichsen serves as a Clinical Associate Professor at the Department of Clinical Medicine within the Faculty of Health and Medical Sciences at the University of Copenhagen. Her clinical specialization focuses on Internal Medicine: Rheumatology, with dual institutional affiliations at Blegdamsvej 9 (2100 Copenhagen Ø) and Blegdamsvej 3 (2200 Copenhagen N) in Denmark. Her research portfolio demonstrates deep expertise in autoimmune rheumatic diseases with particular emphasis on connective tissue disorders and inflammatory myopathies. Key research areas include systemic lupus erythematosus, systemic sclerosis, dermatomyositis, polymyositis, and sporadic inclusion body myositis. Her work frequently explores complications such as cardiovascular risks, cancer associations, and innovative treatment approaches for neuromuscular manifestations. Analysis of her publication trends reveals three dominant research streams: (1) autoimmune disease complications including cancer risks and cardiac outcomes, (2) diagnostic biomarker development for connective tissue diseases, and (3) therapeutic interventions for inflammatory myopathies including physical rehabilitation approaches and targeted treatments. Her recent work shows increasing focus on nationwide cohort studies and translational applications of imaging techniques. Dr. Diederichsen maintains active clinical research collaborations across multiple Danish medical institutions, particularly with Copenhagen University Hospital (Region Hovedstaden) as indicated by her institutional email domain. Her research output demonstrates consistent productivity with publications spanning high-impact rheumatology, neurology, and internal medicine journals.

• Radiation Oncology
• Therapeutic Radiology
• Stereotactic Radiosurgery
• +۷ مورد دیگر

James E. Hansen is an Associate Professor of Therapeutic Radiology at Yale School of Medicine and a key member of Yale Cancer Center. He serves as Chief of the Gamma Knife Program and Co-Director of the Stereotactic Radiosurgery and Body Radiotherapy Fellowship. Dr. Hansen is affiliated with multiple cancer programs including the Center for Gastrointestinal Cancers, Center for Thoracic Cancers, Head & Neck Cancers Program, and Prostate & Urologic Cancers Program. Dr. Hansen specializes in Gamma Knife stereotactic radiosurgery and stereotactic body radiation therapy (SBRT) for treating various cancers including Central Nervous System tumors, Head and Neck cancers, Lung cancer, Lymphoma, Skin cancer, and Gastrointestinal and Genitourinary cancers. His clinical philosophy emphasizes personalized care, as he states: "Every patient journey is unique. Please know that in good times or challenging times, you are never battling this disease alone." Dr. Hansen's research bridges radiation oncology with molecular immunology, focusing on how autoantibodies from autoimmune disorders can be harnessed to fight cancer. He is particularly excited about advancements in drug design that allow treatments to cross the blood-brain barrier, stating: "I have never been more excited and optimistic about the future benefits of therapies that cross the blood-brain barrier and target brain tumors." His work has been featured in media outlets including WTNH News 8, Healio, and Yale Medicine News. His recent publications demonstrate a strong focus on nuclear-penetrating autoantibodies, DNA-targeted cancer therapies, and stereotactic radiation techniques. Dr. Hansen has made significant contributions to understanding how lupus-derived and scleroderma autoantibodies can be repurposed for cancer treatment, including their ability to deliver therapeutic agents across the blood-brain barrier and activate tumor immunity. Dr. Hansen received his medical training at UCLA School of Medicine, followed by residency and chief residency in therapeutic radiology at Yale School of Medicine. He also holds a Master's degree in Biochemistry and Molecular Biology from UCLA. His clinical and research work exemplifies the interdisciplinary approach needed to develop innovative cancer treatments that combine radiation therapy with molecular targeting strategies.

Filemon K. Tanمشاهده پروفایل

استاد

• Autoimmune Diseases
• Rheumatology
• Genetics of Connective Tissue Diseases
• +۵ مورد دیگر

Dr. Filemon K. Tan is a Professor of Medicine at UTHealth Houston McGovern Medical School, where he has built a distinguished career spanning over two decades. He completed his entire medical education and training at UTHealth Houston, joining the faculty as Assistant Professor of Medicine in 1998 and rising to full Professor by 2010. Currently, he holds the prestigious Linda K. Finger Chair in Autoimmune and Connective Tissue Diseases and directs the UT Physicians Rheumatology Clinic at the Texas Medical Center. Dr. Tan's research focuses on genetic factors influencing susceptibility to autoimmune diseases, particularly lupus and scleroderma, and analyzing gene expression patterns to discover disease pathways and potential biomarkers. As one of the Principal Investigators of the Center of Research Translation in Scleroderma, his work bridges basic science and clinical application. His clinical expertise extends to musculoskeletal sonography, where he holds dual certification (RMSK and RhMSUSTM). UTHealth Master Teacher Award (2005) Multiple Dean's Teaching Excellence awards (2005-2014) Elected to Alpha Omega Medical Society (2006) Holds Linda K. Finger Chair in Autoimmune and Connective Tissue Diseases (since 2011) Dr. Tan has demonstrated exceptional commitment to medical education, serving as Program Director for the Rheumatology Fellowship for 13 years (2005-2018). His clinical practice integrates advanced ultrasound techniques with traditional rheumatologic care, providing comprehensive treatment for patients with autoimmune and connective tissue diseases. His research program continues to advance understanding of scleroderma pathogenesis through genetic and molecular approaches.

Michael Whitfieldمشاهده پروفایل

استاد

• Autoimmunity
• Fibrosis
• Systemic Sclerosis
• +۹ مورد دیگر

Michael Whitfield is a Professor of Biomedical Data Science and Professor of Molecular and Systems Biology at the Geisel School of Medicine, Dartmouth College. He serves as the Department Chair of Biomedical Data Science, leading research and academic initiatives in this interdisciplinary field. Dr. Whitfield's research focuses on the molecular basis of autoimmunity and fibrosis, with particular emphasis on systemic sclerosis (SSc). His lab employs genomic and computational approaches including RNA-sequencing, tissue resident microbiome analyses, gene-gene network analyses, and machine learning to interrogate genetic and phenotypic changes in patients. Key research areas include: Identification of molecular subsets in autoimmune diseases Systems biology approaches to analyze patient cohorts with SSc and related fibrotic conditions Development of gene expression biomarkers to subset patients and predict clinical endpoints Creation of three-dimensional (3D) tissue culture models (self-assembled Skin Equivalents) to study SSc fibroblast activation Analysis of Dr. Whitfield's recent publications reveals a strong focus on scleroderma research, with particular attention to clinical applications of genomic findings. His work bridges computational biology with clinical medicine, seeking to identify common mechanisms driving disease across multiple organ systems in patients with SSc and related conditions. Dr. Whitfield leads the Whitfield Lab, which utilizes genome-wide, systems biology approaches to study scleroderma. The lab investigates this rare autoimmune disease with heterogeneous clinical presentation, focusing on identifying gene expression biomarkers that can improve patient classification, predict clinical outcomes, and assess treatment responses. The lab's work on 3D tissue culture models represents an innovative approach to studying fibroblast activation in a more physiologically relevant microenvironment.